Daré Bioscience Provides Business Update and Announces Third Quarter Financial Results
November 13, 2018 07:30 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today provided a business update and announced financial...
Daré to Host Third Quarter 2018 Financial Results Conference Call and Webcast
November 06, 2018 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it will host a conference call and live...
Daré Announces Two Late-Breaking Abstracts to be Presented at the American Association of Pharmaceutical Scientists (AAPS) in Washington D.C.
October 30, 2018 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it will be presenting two late-breaking...
Daré Bioscience, Inc. to Present at the Dawson James Small Cap Growth Conference
October 23, 2018 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that John Fair, Chief Business Officer, will...
Daré Bioscience, Inc. to Present an Overview of Novel Intra-Vaginal Ring (IVR) Technologies at the Partnership Opportunities in Drug Delivery (PODD) Meeting Held in Boston, MA October 17th – 18th
October 15, 2018 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s health-focused biopharmaceutical company, today announced it will be presenting...
Daré Bioscience, Inc. to Present at the 2018 BIO Investor Forum
October 10, 2018 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that Sabrina Martucci Johnson, President and...
Greg Matz Joins Daré Bioscience Board of Directors
September 17, 2018 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of Greg Matz to its board of...
Daré Bioscience, Inc. to Present at the H.C. Wainwright 20th Annual Global Investment Conference
August 30, 2018 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that John Fair, Chief Business Officer, will...
Daré Bioscience, Inc. to Present at the Canaccord Genuity 38th Annual Growth Conference
August 02, 2018 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that John Fair, Chief Business Officer, will...
Daré Bioscience, Inc. Announces Asset Transfer Agreement with Hydra Biosciences, Inc. for CatSper Contraceptive Target
July 16, 2018 08:00 ET
|
Dare Bioscience, Inc.
CatSper antagonist has potential to provide pregnancy prevention via administration to either women or men as a novel, rapidly reversible, non-hormonal contraceptive SAN DIEGO, July 16, 2018 ...